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Abstract: Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is the first available agent in 
a new class of antiretroviral drugs. Raltegravir has been studied extensively in clinical trials, and 
has been well tolerated and highly effective in both treatment-naïve and -experienced patients. 
Resistance to raltegravir is unusual given its recent availability, but resistance with identified 
viral mutation pathways in the integrase gene in patients receiving the drug does occur.
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Introduction
Recent years have witnessed dramatic changes in the management of patients infected 
with human immunodeficiency virus (HIV). International guidelines have been updated, 
and experts are now recommending beginning antiretroviral therapy (ART) earlier in 
the course of infection.1 Data from several large international cohort studies indicate 
that unchecked viremia and delayed therapy not only increase the risk of opportunistic 
infection, but also the incidence of cardiovascular disease, renal disease, malignancy, 
and overall mortality.2,3 Recent guidelines recommend that clinicians obtain resistance 
testing at baseline, given the problem of transmitted viral resistance. The prevalence of 
transmitted resistance is variable, and is estimated to occur in as many as 10% of new 
infections.4 Increasing numbers of previously treated patients harbor virus resistant 
to drugs in each of the three original classes of antiretrovirals: the nucleoside reverse 
transcriptase inhibitors (NRTI), non-NRTIs, and protease inhibitors (PI). To help 
overcome these hurdles, several new fixed-dose combination (FDC) regimens and 
drugs with entirely new mechanisms of action are now available: the CCR5-coreceptor 
inhibitors and the integrase (IN) inhibitors.
Raltegravir (Isentress®; Merck and Co., Inc., Whitehouse Station, NJ, USA), an 
inhibitor of the HIV-1 IN enzyme, is the first agent in a new class of antiretroviral 
drugs. Initially approved in 2007 for the treatment of patients infected with 
multi-drug resistant HIV, raltegravir was recently also approved by the US Food and 
Drug Administration (FDA) for ART-naïve patients. Raltegravir has been studied 
  extensively in clinical trials and has been shown to be highly effective and well 
tolerated. Resistance to raltegravir is still unusual given its recent availability, but 
mutation pathways in the IN gene that develop in patients receiving the drug has been 
observed.5 In this review recent developments in clinical research involving raltegravir 
and its role in the management of treatment-naïve and -experienced HIV-infected 
patients are discussed.Infection and Drug Resistance 2010:3 16
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Pharmacology, mode of action,  
and pharmacokinetics
HIV integrases are versatile transferases able to remove 
and transfer portions of double-stranded polyribonucleotide 
  substrate to another gene location.6 In practical terms, 
  following reverse transcription, HIV IN allows proviral DNA 
to integrate into host cell DNA, leading to transcription and 
production of new infectious virions.7
IN is a 288-amino acid protein encoded along with 
  protease and reverse transcriptase by the pol gene. It has three 
independent domains, serving as three potential drug targets: 
the N-terminal domain, the central or catalytic domain, and 
the C-terminal domain. IN binds each end of viral DNA 
and catalyzes endonucleotide cleavage from each end 
(3′ processing). The cleaved DNA forms the pre-integration 
complex, followed by strand transfer with joining of viral 
and cellular DNA (integration).7,8 Raltegravir is a strand-
transfer inhibitor (INSTI), and blocks docking of the enzyme 
to target DNA, inhibiting viral integration. Although other 
potential targets within viral IN are under investigation, the 
strand-transfer inhibitors are the only agents to date that have 
progressed to phase III clinical trials.6
Pharmacokinetic studies demonstrate potent in vitro 
activity of raltegravir against HIV-1, with a 95% inhibitory 
concentration (IC95) of 33 nM in 50% human serum.9 The 
drug is rapidly absorbed, with median time to peak plasma 
concentration ranging from 0.5 to 1.3 hours, and steady state 
is achieved within 2 days of multiple-dose administration. 
Overall pharmacokinetic parameters following a single dose 
of 400 mg are similar in males and females.9
The approved clinical dose of raltegravir is 400 mg 
orally twice daily. The drug is metabolized primarily 
via glucuronidation mediated by the uridine diphosphate 
  glucuronosyl transferase 1A1 isoenzyme (UGT 1A1), leading 
to relatively few drug – drug interactions in comparison 
to agents metabolized primarily by cytochrome P450 
enzymes. Inducers or inhibitors of UGT 1A1 may have 
an effect on raltegravir concentrations. For example, two 
pharmacokinetic studies found that coadministration of 
rifampin, a UGT 1A1 inducer, resulted in lower plasma 
raltegravir concentrations; increasing the raltegravir dose to 
800 mg twice daily compensates for this effect on raltegravir 
exposure (increases the area under the curve [AUC]) but 
does not overcome the effect on trough concentrations.10 
Coadministration of rifampin with raltegravir should thus 
be undertaken with caution. Tipranavir, a protease inhibi-
tor coadministered with ritonavir used for the treatment 
of drug-resistant HIV-1, is also an inducer of UGT 1A1. 
Although raltegravir concentrations at 12 hours (C12) were 
decreased when coadministered with tipranavir in healthy 
subjects, other pharmacokinetic parameters were not 
  substantially affected, and there were no differences in safety 
or efficacy profiles.11 Atazanavir, a protease inhibitor used 
frequently in the treatment of HIV-1, is an inhibitor of both 
cytochrome P450 3A and UGT 1A1. When coadministered 
with raltegravir to healthy subjects in multiple doses, 
atazanavir and atazanavir plus ritonavir modestly increased 
plasma levels of raltegravir.12 Raltegravir is more soluble 
at basic gastric pH levels, and coadministration of proton-
pump inhibitors, such as omeprazole, results in increased 
plasma concentrations of raltegravir (3- to 4-fold increase in 
AUC).13 No dosage adjustments are currently recommended 
when atazanavir, tipranavir, or omeprazole are administered 
with raltegravir.
Raltegravir is administered without regard to food. 
No clinically important pharmacokinetic differences were 
observed in subjects with severe renal impairment or mild 
to moderate hepatic impairment, so no dose adjustments are 
recommended in patients with these conditions.14
Clinical efficacy: treatment-naïve 
patients
Based on efficacy data in treatment-naïve patients from 
Protocol 004 and STARTMRK, raltegravir was approved for 
use in this patient population by the FDA in mid 2009.15–18 
Part 1 of Protocol 004 randomized 35 ART-naïve patients 
to placebo or to raltegravir at four different doses (100 mg, 
200 mg, 400 mg or 600 mg) administered twice daily for ten 
days. In all cases, raltegravir resulted in dramatic reductions 
in HIV-1 RNA (approximately a 2.0 log10 reduction), and 
at least 50% of patients receiving any dose of raltegravir 
achieved a viral load of 400 copies/mL by day 10.15 In part 2 
of the protocol 198 ART-naïve patients with HIV-1 RNA 
levels of at least 5,000 copies/mL and CD4+ cell counts of 
at least 100 cells/mm3 were randomized to receive efavirenz 
600 mg or raltegravir (at one of the above four doses) with 
a nucleoside backbone of tenofovir 300 mg and lamivudine 
300 mg.16 All drugs were dosed daily, except for raltegravir, 
which was dosed twice daily, as in Part 1. At 48 weeks all 
patients receiving raltegravir were stratified into one group 
receiving 400 mg twice daily, to continue through 96 weeks.17 
More than 90% of patients receiving any dose of raltegravir 
achieved HIV-1 RNA levels of 400 copies/mL by week 4, 
and through week 8 more patients receiving raltegravir than 
efavirenz achieved HIV-1 RNA levels of 50 copies/mL. 
Thus, viral load reduction was more rapid in patients on Infection and Drug Resistance 2010:3 17
Raltegravir in combination for HIV infection Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
raltegravir, although the proportion of patients in each group 
with virologic suppression to 50 copies/mL was similar at 
24 and 48 weeks.16 Three percent of patients in each group 
experienced virologic failure: 2 patients who had failed a 
raltegravir-based regimen were found to have the N155H 
mutation. At week 96, 83% of patients in the raltegravir group 
and 84% of patients in the efavirenz group had achieved 
HIV-1 RNA levels of 50 copies/mL.17 Patients in both 
groups had similar increases in CD4+ cell count (221 vs 
232 cells/mm3, respectively). One additional patient in each 
group experienced virologic failure, although no integrase 
resistance mutations were identified.
STARTMRK is an ongoing international, randomized, 
double-blind, Phase III study comparing raltegravir 400 mg 
twice daily to efavirenz 600 mg nightly, both in combination 
with tenofovir 300 mg and emtricitabine 200 mg in FDC.18 
Patients naïve to ART, aged 18 years or older, with HIV-1 
RNA levels of 5,000 copies/mL were eligible for study 
entry. Patients were excluded if they had renal insufficiency or 
decompensated hepatitis; patients with chronic hepatitis were 
eligible if their serum aminotransferase levels were less than 
5 times the upper limit of normal. Pregnant or breastfeeding 
women were excluded, as were patients with documented 
genotypic resistance to tenofovir, emtricitabine, or efavirenz. 
Virologic failure was defined as either nonresponse (those 
who did not achieve a viral load of 50 copies/mL at any 
stage during the study) or rebound (those who had a viral load 
of 50 copies/mL on 2 consecutive measurements after an ini-
tial response to treatment).18 Virologic failure was investigated 
by genotyping of the integrase coding sequence.
Eighty-six percent of patients in the raltegravir arm 
achieved a viral load of 50 copies/mL at week 48, 
  compared with 81.9% in the efavirenz arm (P  0.001 for 
  noninferiority). Of note, the time to achieve viral suppression 
was significantly shorter for patients on raltegravir than for 
those on efavirenz (P  0.001). Although the exact mecha-
nism is unknown, this rapid decay in viremia has been attrib-
uted to raltegravir’s inhibition of reverse transcribed HIV 
DNA into the host genome, a step that occurs later in the 
viral life cycle.19 Additionally, patients receiving raltegravir 
had greater increases in CD4+ cell counts from baseline 
at week 48 (189 cells/mm3 vs 163 cells/mm3 for efavirenz 
recipients (P  0.02).18
Ten percent of patients on raltegravir vs 14% on efavirenz 
failed to achieve HIV-1 RNA levels 50 copies/mL. 
Genotypic susceptibility testing was performed on 15 patients 
who had sufficient virus for amplification. Four of 8 patients 
on raltegravir had virus with integrase mutations (2 had 
G140S, Q148H/R, 1 had Y143Y/H, 1 had Y143R), and 3 
of the 7 patients on efavirenz had RT mutations (all 3 had 
K103N).18
Significantly more patients on efavirenz had drug-
related clinical adverse events, in particular, central 
  nervous system (CNS)-related. The most common adverse 
events were dizziness (6% raltegravir arm, 34% efavirenz), 
headache (9% vs 14%, respectively), and abnormal dreams 
(7% vs 13%, respectively).
There have been no known cases to date of raltegravir-
resistant virus in newly infected individuals. The availability 
of raltegravir and other drugs in new classes may therefore 
prove particularly useful in such cases of transmitted 
resistance, for example, to nonnucleoside reverse transcriptase 
inhibitors, given the theoretical risk of suboptimal response 
to standard first-line regimens.
Clinical efficacy: treatment-
experienced patients
Given its activity against HIV-1 with reverse transcriptase 
and/or protease mutations, raltegravir was initially approved 
in 2007, and is increasingly utilized for the treatment of 
multi-drug resistant virus. Its safety and efficacy in this 
setting have been demonstrated in multinational randomized 
Phase II and III clinical trials. In Protocol 005, patients with 
HIV-1 RNA levels of greater than 5000 copies/mL, CD4 cell 
counts above 50 cells/mm3, and genotypic or phenotypic 
resistance to at least one NRTI, non-NRTI, and PI, received 
raltegravir or placebo in combination with optimized back-
ground therapy (OBT) as determined by the investigator.20
Patients in raltegravir arms received one of three doses: 
200, 400, or 600 mg twice daily. In both Phase II and III trials, 
genotypic and phenotypic sensitivity scores (GSS and PSS, 
respectively) represented the total number of active drugs in 
the OBT. The Protocol 005 patient population was highly 
treatment experienced, having received a median of 12 anti-
retroviral agents per patient, with a median of 4 drugs in the 
OBT. Thirty-six percent of patients were on enfuvirtide. At 
week 24, patients receiving any dose of raltegravir achieved 
significantly greater degrees of viral suppression than did 
those receiving placebo with OBT (mean change in viral 
load from baseline was −1.80 log10 copies/mL in the 200 mg 
group, −1.87 log10 copies/mL in the 400 mg group, −1.84 log10 
copies/mL in the 600 mg group, and −0.35 log10 copies/mL 
for the placebo group, P  0.001).20 Increases in CD4 counts 
were also significantly greater in all raltegravir groups com-
pared to placebo, and treatment differences were consistent 
across all GSS and PSS.Infection and Drug Resistance 2010:3 18
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The BENCHMRK studies are ongoing randomized, 
  double-blind, placebo-controlled Phase III trials similar in 
design to Phase II: BENCHMRK-1 in Europe, Asia, Australia, 
and Peru; BENCHMRK-2 in North and South America.5,21 
Patients were enrolled at a 2:1 ratio to receive either raltegravir 
400 mg twice daily or placebo, both with OBT. The most 
recent data from BENCHMRK are 96 week results presented 
at the Conference on Retroviruses and Opportunistic 
  Infections (CROI) in February of 2009; the planned study 
duration is 256 weeks.22 As in Protocol 005, OBT was selected 
by the investigator based on previous treatment history 
and resistance testing, and results were stratified by GSS, PSS, 
and first use of darunavir or enfuvirtide. Patients were required 
to have an HIV-1 RNA level of greater than 1000 copies/mL 
and documented triple-class resistance on entry into the 
trial. The median CD4 counts and mean baseline viral loads 
were similar in the raltegravir and placebo-based groups 
(CD4 119 vs 123 cells/mm3, respectively; and viral load 
44,897 and 39,059 copies/mL, respectively).22 Twenty-five 
percent of patients in the raltegravir arm, and 28% of those 
on placebo had a GSS of zero.
Although the BENCHMRK patient population represents 
a highly treatment-experienced group with multi-drug 
resistant virus, 96-week data reveal sustained and potent 
viral load reduction and CD4 count reconstitution in patients 
on raltegravir plus OBT, in comparison with placebo 
(Figures 1 and 2). Fifty-seven percent of patients on 
raltegravir had HIV-1 RNA levels of 50 copies/mL at 
96 weeks, compared to 26% on placebo (P  0.001, adjusted 
for baseline viral load, and first use of enfuvirtide, darunavir, 
or active PI in OBT). Change from baseline CD4 cell count 
was also significantly greater in patients receiving raltegravir 
plus OBT compared to placebo (123 vs 49 cells/mm3, 
respectively, P  0.001).22
Figure 3 depicts rates of viral suppression at week 96 
stratified by GSS. As expected, patients with more active 
agents in their OBT had higher rates of virologic suppression 
in both the raltegravir and placebo arms (65% vs 53%, 
respectively, with a GSS of 2). The most dramatic 
  difference was observed between arms in patients who had 
no active agents in their OBT, or a GSS of 0. These patients 
who received raltegravir had a rate of viral suppression to 
less than 50 copies/mL at 96 weeks of 41%, compared to 
5% who received placebo plus OBT.22 Those who received 
either darunavir or enfuvirtide for the first time as part of 
their OBT also did significantly better than those who did not. 
The rates of virologic suppression in patients receiving both 
these agents in their OBT were similar between the two arms 
(79% on raltegravir, 63% on placebo), whereas patients with 
neither darunavir or enfuvirtide in their OBT did significantly 
better on raltegravir (56% suppressed to 50 copies/mL, 
compared to 19% on placebo).
Occurrence of AIDS-defining conditions (ADC) and 
death was examined at 48 weeks as a secondary endpoint 
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in BENCHMRK. The median time to first new or recurrent 
ADC was 9.1 weeks in the raltegravir arm and 15 weeks in the 
placebo arm. The incidence rate of new ADCs or death was 
lower for patients on raltegravir (3.00 per 100 person-years 
[PYR] vs 6.78 per 100 PYR for placebo), but differences 
were not statistically significant. The most common ADC 
in both groups was esophageal candidiasis.23
Virologic failure was defined as failure to achieve HIV-1 
RNA levels of 400 copies/mL or less than a 1 log10 drop 
from baseline by week 16. Patients were also considered to 
have failed virologically if they experienced an increase in 
HIV-1 RNA of more than 1 log10 copies/mL from the nadir 
level on 2 consecutive measurements, or 2 consecutive lev-
els of greater than 400 copies/mL after having achieved a 
level of less than 400 copies/mL.21 Twenty-five patients had 
virologic failure between weeks 48 and 96: 17 of 370 on 
raltegravir plus OBT, 8 of 105 patients on placebo plus OBT.22 
Of the 17 patients who failed on raltegravir, 11 had genotype 
analysis, and 7 had known raltegravir resistance mutations. 
Of note, three of these patients had a GSS of 0, and one had 
a GSS of 1. The most common major IN mutation was the 
N155H, present in all but one of the above seven patients. 
Two patients had the Q148 (one Q148H, one Q148R), and one 
had the Y143C. A variety of minor mutations were present in 
the seven patients.22 These results are consistent with what is 
currently understood about the development of resistance to 
IN inhibitor therapy: failure on raltegravir generally occurs 
when no other fully active drugs are included in the OBT, 
and is represented most commonly by the Q148H/K/R or 
N155H major mutations in combination with a variety of 
minor mutations. Raltegravir failure is associated with IN 
mutations in one of these two genetic pathways, defined by 
at least two mutations, including a major mutation at either 
Q148/K/R or N155H and at least one minor mutation. The 
most common pathway to IN inhibitor resistance is Q148H 
plus G140S. Major mutations reduce susceptibility and viral 
replication capacity, whereas minor mutations emerge later 
and enhance resistance while improving replication capacity.4 
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Based on data from Protocol 005 and BENCHMRK, when 
considering the use of raltegravir for treatment-experienced 
individuals, it is imperative to include at least one other fully 
active agent in a treatment regimen, as patients receiving 
functional monotherapy with raltegravir are at high risk for 
virologic failure due to the development of mutations in IN. 
Retrospective and in vitro analyses were performed based 
on 48 week resistance data: baseline and virologic failure 
samples were available for 94 of the 105 patients who failed 
on raltegravir plus OBT at that time point.24 The Q148 path-
way was selected over time, and conferred a larger reduction 
in raltegravir susceptibility than the N155 pathway. Both 
pathways reduced replication capacity, but the effect of minor 
mutations on replication capacity varied depending on the 
primary mutation. Fransen and colleagues also reported the 
exclusive association of G140A/S with Q148 mutations, and 
E92Q with N155H mutations.25 In general, the addition of 
secondary mutations enhanced resistance to raltegravir, and 
in some cases partially restored replication capacity.
Clinical efficacy: novel combinations 
and switch studies
The availability of raltegravir has led clinicians to utilize 
novel strategies in managing complex patients. For example, 
many NRTIs, in particular the thymidine analogues, such 
as stavudine, didanosine, and zidovudine, are associated 
with longitudinal toxicities, such as lipoatrophy and 
peripheral neuropathy, leading to the consideration of 
“nucleoside-sparing” regimens. Before the advent of the IN 
inhibitor class this regimen could only have consisted of an 
NNRTI and a PI, or a dual PI regimen. Medications in both 
these classes have shown to cause considerable toxicity, 
including increase in LDL cholesterol.26 Preliminary data 
on the combination of an unboosted PI, atazanavir, with 
raltegravir for treatment-experienced patients, were presented 
at the International AIDS Society Conference in Cape Town, 
South Africa, in July 2009.27 This was a single-arm, open-label 
pilot study, in which 27 treatment-experienced patients who 
were NRTI intolerant or had demonstrated NRTI resistance 
were switched from their current regimen to raltegravir 
400 mg and atazanavir 200 mg twice daily. Patients were 
ineligible for the study if they had previously received ralte-
gravir or had documented PI resistance. Use of proton-pump 
inhibitors was not permitted. The primary endpoint of the 
study was HIV-1 viral load of less than 50 copies/mL at 
week 48. Twenty-two patients were already on PI-containing 
ART, and a majority (22 of 27) switched regimens due to 
intolerance or toxicity. Only five patients changed regimens 
due to NRTI resistance. Ninety-three percent of patients 
achieved and maintained virologic suppression to less than 
50 copies/mL by week 24: of the two patients who failed 
to achieve suppression, one had developed the N155H IN 
mutation. Both had detectable HIV-1 viral loads at baseline. 
The regimen was well tolerated, with no dose reductions or 
significant adverse events. An increase in serum bilirubin 
was noted in a majority of patients. There were no significant 
changes in liver or renal function, and serum lipids did 
not change significantly at week 24. Mean serum creatine 
phosphokinase increased significantly from study inception 
to week 24 (127 to 148 IU/L, P  0.05).
Although these results are promising, it is important to 
note the small size and nonrandomized, open-label nature 
of this study. Investigations of other INSTI-containing, 
NRTI-sparing regimens are ongoing, including raltegravir 
in combination with darunavir/ritonavir and lopinavir/
ritonavir. Results from controlled randomized trials 
  comparing NRTI-containing vs NRTI-sparing regimens will 
help establish the role of these regimens in various patient 
populations.
Results from additional “switch” studies were recently 
presented, in which raltegravir was substituted for other 
agents in patients with undetectable viral loads due to toxicity 
and/or intolerance.28,29 The EASIER investigators randomized 
170 patients with triple-class resistance or intolerance 
virologically suppressed to less than 400 copies/mL for at 
least 3 months on enfuvirtide-containing regimens either to 
continue the current regimen (n = 85), or to switch enfuvirtide 
to raltegravir (n = 85).28 The study was undertaken due to the 
high incidence of patient dissatisfaction among patients on 
enfuvirtide, owing primarily to injection-site reactions and 
the inconvenience of twice-daily subcutaneous injections. 
At 24 weeks, similar numbers of patients in each arm had 
achieved HIV-1 RNA levels of less than 50 copies/mL: 88% 
in the enfuvirtide arm, 89% in the raltegravir arm. One patient 
in each arm experienced virologic failure, and there were 
no significant changes in either arm in CD4+ cell counts 
through 24 weeks.
The SWITCHMRK29 trials examined a switch from 
a suppressive lopinavir/ritonavir-based regimen in 
treatment-experienced patients to a raltegravir-based regimen 
in terms of maintenance of viral suppression as well as lipid 
profiles. Although lopinavir/ritonavir is a potent PI with 
well-documented efficacy and durability, it is associated with 
significant elevations in serum lipid levels. Protocols 032 and 
033 are parallel, randomized, multinational, double-blind 
trials. The approximately 350 patients enrolled in each Infection and Drug Resistance 2010:3 21
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  protocol were required to have undetectable HIV-RNA levels 
for at least 3 months on a lopinavir/ritonavir-based regimen 
containing at least 2 NRTIs. Lipid-lowering therapy in the 
12 weeks preceding study entry was not permitted. Of note, 
patients in both arms of each protocol had extensive treatment 
experience (median duration of previous ART 3.3 years in 
the raltegravir arm and 3.6 years in the lopinavir/ritonavir 
arm in Protocol 032; 3.7 vs 4.6 years, respectively, in Proto-
col 033). For the primary endpoint of HIV-1 RNA less than 
50 copies/mL, noninferiority criteria were pre-specified as 
a lower limit of the 95% confidence interval (CI) of less 
than or equal to 12%. Mean changes in lipid parameters 
were analyzed at week 12. In both SWITCHMRK 1 and 
2, patients in the raltegravir arms less often maintained 
HIV-1 RNA levels of less than 50 copies/mL (81 vs 87% in 
  Protocol 032; 88 vs 94% in Protocol 033), and thus did not 
meet noninferiority criteria for viral suppression. However, 
there were significant improvements in lipids at week 12 
in the raltegravir arms, with fasting total cholesterol, non-
HDL cholesterol, and triglycerides statistically significantly 
lower in raltegravir arms. Pooled data from the parallel trials 
were examined to investigate further the increased rates of 
  virologic failure in patients switched to raltegravir: failure 
was confirmed in 32 patients on raltegravir and in 17 patients 
on lopinavir/ritonavir. Resistance analysis was available 
for 10 patients from SWITCHMRK 2, two of whom failed 
raltegravir. Genotypic analysis revealed 7 of these patients 
harbored integrase mutations at the time of virologic failure, 
including 5 patients with the N155H, 5 with the Q148R/H, 
and 2 with the Y143C/S. Four of these patients also harbored 
multiple reverse transcriptase mutations, all had the M184V . 
While definitive explanations for these disparities are still 
elusive, it is likely that this treatment-experienced group of 
patients who had achieved viral suppression on lopinavir/
ritonavir harbored some degree of NRTI resistance at study 
entry, thereby increasing the theoretical risk of failure. Ralte-
gravir performs best when combined with other, presumably 
fully active agents. This will likely occur more often with 
newer medications. Investigators examined the incidence of 
virologic failure in 143 heavily treatment experienced patients 
receiving raltegravir for the first time in combination with 
other agents, and found that rates of failure were lowest with 
raltegravir-containing regimens that included darunavir/rito-
navir, maraviroc, enfuvirtide, or etravirine (2%). Twenty-six 
percent of patients whose regimens did not include one of 
these agents experienced failure (P  0.001).30 The ANRS 
139 TRIO trial31 examined the use of raltegravir, etravirine 
and ritonavir-boosted darunavir for the treatment of patients 
with multidrug-resistant virus. Patients enrolled were naïve to 
the three study drugs, and 87% also received OBT. At week 
48, 86% (95% CI 80% to 93%) of patients had an HIV RNA 
level of less than 50 copies/mL, and the median increase 
in CD4 cell count was 108 cells/mm3. These recent data 
underscore the important concept of combining raltegravir 
with other active agents, in order to maximize its efficacy 
and durability.
Safety and tolerability
Raltegravir is generally very well tolerated, and its safety 
in different patient populations has been demonstrated 
repeatedly in clinical trials. Initial Phase I studies that tested 
varying doses of the drug confirmed safety of raltegravir 
monotherapy at doses up to 1600 mg daily for 10 days, and 
there were no drug-related discontinuations.15 The most 
common drug-related side effects reported were headache 
and fatigue characterized as mild to moderate in intensity. 
The most recent results from the largest clinical trials 
involving raltegravir administration to treatment-naïve and 
-experienced patients, STARTMRK and BENCHMRK, 
respectively, confirm its safety and tolerability.18,22
Most of the 566 patients enrolled in the STARTMRK18 
trials experienced at least one clinical adverse event (AE), but 
more were receiving efavirenz (95.6% vs 90% on raltegravir). 
Importantly, clinical AEs judged by investigators to be 
drug-related were significantly greater in efavirenz arms 
(77% vs 44% in raltegravir arms, P  0.001). There were 
no significant differences in rates of serious AEs or AEs 
leading to study discontinuation between groups. Specific 
AEs occurring in more than 10% of patients on either drug 
were dizziness, headache, and abnormal dreams: all were 
more common in patients receiving efavirenz. Significantly 
more patients on efavirenz had experienced neuropsychiatric 
symptoms by week 8 (52% vs 20% on raltegravir, P  0.001). 
At least 2% of patients in either arm experienced the 
following laboratory-associated AEs: elevated aspartate 
aminotransferase and elevated alanine aminotransferase. 
Grade 3 or 4 laboratory-associated AEs were generally 
uncommon, and occurred with similar frequency in each of 
the study arms.
Ninety-six week data from the BENCHMRK trials22 
yielded similar results with regard to raltegravir safety 
and tolerability in treatment-experienced patients on OBR. 
Thirty-three percent of the 462 patients on raltegravir plus 
OBT vs 52% of patients on placebo plus OBT experienced a 
drug-related AE (P = NS), and 3.7% of patients on raltegravir 
discontinued drug due to an AE (vs 5.1% on placebo). Infection and Drug Resistance 2010:3 22
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The most common clinical AEs were diarrhea, nausea, 
and headache in both groups: only fatigue and abdominal 
  distension were more common in raltegravir arms. Grade 3 
or 4 laboratory abnormalities were equally uncommon in each 
arm; grade 4 elevations of creatine kinase (20.0 times the 
upper limit of normal) occurred in 3% of patients receiving 
raltegravir and 0.8% of patients on placebo. Cancer events 
were similar in frequency as well: 3% vs 2.6% in raltegravir 
and placebo groups, respectively, yielding a relative risk of 
1.1 (95% CI 0.5, 3.1). Further analysis including data from all 
double-blind Phase II and III studies resulted in malignancy 
rates of 1.7/100 PYR for raltegravir, and 2.2/100 PYR for 
comparator groups (relative risk of 0.8, 95% CI 0.4, 1.5).32
Conclusions
Raltegravir, the first INSTI, is currently approved for the 
treatment of HIV-1 infection in patients naïve to antiretroviral 
therapy, and heavily treatment-experienced. It retains 
activity against virus with known reverse transcriptase and 
protease mutations and both CCR5- and CXCR4-tropic 
virus. To date there is little known transmitted integrase 
resistance. Raltegravir has been proven non-inferior to 
standard recommended regimens in terms of virologic and 
  immunologic efficacy, as well as safety and tolerability, and 
may in fact be better tolerated than most alternative regimens. 
Specifically, raltegravir has more favorable effects on lipids 
than comparator drugs efavirenz and lopinavir/ritonavir, 
and to that end may be a reasonable option for patients with 
hyperlipidemia and other cardiovascular risk factors. In 
an aging HIV-infected patient population with accelerated 
metabolic and vascular complications, raltegravir may prove 
particularly useful. Although available data from switch 
studies has been somewhat promising, there is ongoing 
concern with regard to the relatively low resistance barrier 
and potential for failure on raltegravir-based regimens that 
lack at least one other active agent. Results from controlled, 
blinded switch studies are forthcoming and will be important 
in considering these treatment strategies.
Raltegravir may find its place in other treatment 
  situations in the near future, given its rapid and profound 
viral suppression. Potential areas of investigation include 
its use for post-exposure prophylaxis, acute infection, and 
prevention of perinatal infection. We may also see increasing 
raltegravir use in the context of class-sparing strategies, 
a concept also under current investigation.
In summary, the first integrase inhibitor has been a timely 
addition to our armamentarium of antiretroviral therapies. It has 
proven highly effective in patients with multidrug-resistant 
HIV-1 infection, and is safe and effective in newly diagnosed 
patients. Results from ongoing investigations of raltegravir use 
in novel treatment strategies and patient populations will help 
determine the breadth of its use as the epidemic continues to 
affect an aging HIV-infected population.
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